沙美特罗替卡松对哮喘患儿嗜酸粒细胞和免疫球蛋白E及肺功能转归的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the influence of Salmeterol and Fluticasone Propionate (Seretide)on peripheral blood eosinophils(EOS),immunoglobulin E(IgE)and pulmonary function outcome in asthmatic children patients.Methods A total of 62 children patients with asthma in our hospital from March 2015 to September 2017 were selected for the study and were divided into the control group (n=31)and the observation group (n=31).The control group was given Fluticasone Propionate aerosol inhalation,and the observation group was given Salmeterol and Fluticason aerosol inhalation.The clinical efficacy was recorded in the two groups,and the levels of peripheral blood EOS and IgE,and pulmonary function(forced vital capacity[FVC],forced expiratory volume in 1 second[FEV1],peak expiratory flow rate[PEF])were compared between the two groups before treatment and after 4 weeks of treatment.Results The efficacy in the observation group was better than that in the control group,with significant difference(P＜0.05).After 4 weeks of treatment,the levels of peripheral blood EOS and IgE in the observation group were lower than those in the control group,with significant difference (P＜0.05),while the levels of FVC,PEF and EFV1were higher than those in the control group,with significant difference (P＜0.05).After treatment,the levels of EOS and IgE in peripheral blood were lower than those before treatment(P＜0.05),while the levels of FVC,PEF and FEV1were higher than those before treatment(P＜0.05).Conclusion Salmeterol and Fluticasone Propionate can not only reduce the inflammatory response of asthmatic children patients and improve the immune function,but also enhance pulmonary function,and it is favorable for disease outcome.

Key words： Infantile asthma Salmeterol and Fluticasone Propionate Pulmonary function Eosinophil IgE

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Guo-hua
	PAN Zhi-wei
	BAI Jun
	CHEN Liang

Cite this article:

CHEN Guo-hua,PAN Zhi-wei,BAI Jun, et al. Influence of Salmeterol and Fluticasone Propionate on eosinophil and immunoglobulin E and pulmonary function outcome in children patients with asthma[J]. 中国当代医药, 2018, 25(13): 13-15转19.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I13/13

[1]	李桂媚，李欣其.匹多莫德与甘露聚糖肽治疗小儿哮喘临床疗效的比较研究[J].实用心脑肺血管病杂志，2016，24（1）：55-57.
[2]	李敏，魏朝霞.沙美特罗替卡松和糖皮质激素气雾剂治疗小儿哮喘的效果比较[J].医学综述，2017，23（17）：3529-3532.
[3]	江载芳，申昆玲，沈颖.诸福棠实用儿科学[M].8版.北京：人民卫生出版社，2015：706.
[4]	唐瑜琦，赵德辉，孙维佳，等.细菌溶解产物胶囊治疗哮喘急性发作患儿的临床观察[J].中国药房，2017，28（32）：4537-4540.
[5]	代传林，潘家华.儿童支气管哮喘药物治疗进展[J].中华全科医学，2016，14（12）：1974-1975.
[6]	彭芬，黄华，钱炜.糖皮质激素对哮喘患儿的临床疗效及作用机制研究[J].中国临床药理学杂志，2016，32（1）：3-5.
[7]	黄肖梅，黄卫娟，陈建江，等.沙美特罗替卡松单用与丙酸氟替卡松联合孟鲁司特钠治疗儿童中度持续哮喘的疗效比较[J].中国药房，2016，27（23）：3240-3243.
[8]	张理科，陈宇.沙美特罗替卡松治疗中重度支气管哮喘的临床观察[J].中国药房，2016，27（23）：3270-3272.
[9]	詹璐，赵小芳，余忠红，等.沙美特罗替卡松粉联合孟鲁司特对哮喘患儿症状改善的影响[J].西部医学，2015，27（9）：1309-1311.
[10]	姜增凯，贾萍，叶晓歌.孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效及其对炎性因子、肺功能、免疫功能的影响研究[J].实用心脑肺血管病杂志，2016，24（4）：49-52.
[11]	曾霞，陈实.沙美特罗替卡松粉吸入治疗对儿童哮喘肺功能的影响及疗效观察[J].海南医学，2015，26（2）：256-257.
[12]	张朝霞.“冬病夏治”穴位贴敷对哮喘患儿肺功能的影响[J].中医学报，2016，31（3）：337-339.
[13]	邢学伟，葛昌玲.沙美特罗联合孟鲁司特钠对小儿支气管哮喘肺功能及TNF-α、NO、ET表达的影响[J].广西医科大学学报，2017，34（8）：1185-1188.
[14]	常秀，酒兰慧.沙美特罗替卡松治疗支气管哮喘及对患者血浆内皮素及肿瘤坏死因子α的影响[J].中国临床医生杂志，2016，44（1）：89-92.
[15]	刘润宁，余长缨，应林燕，等.孟鲁司特纳片联合沙美特罗替卡松粉吸入剂对儿童支气管哮喘的临床疗效[J].现代生物医学进展，2015，15（8）：1530-1533.
[16]	刘杰，吴向玲，王园园，等.沙美特罗氟替卡松联合孟鲁司特治疗咳嗽变异性哮喘疗效观察[J].医学综述，2016，22（4）：795-797.
[17]	傅英莉，姚丽丽.沙美特罗氟替卡松粉吸入剂联合小剂量阿奇霉素治疗慢性中度持续期哮喘患儿的疗效观察[J].实用临床医药杂志，2016，20（21）：159-160.
[18]	姜水菊，沈水杰，尚云飞.小青龙颗粒联合沙美特罗氟替卡松治疗支气管哮喘急性发作的临床观察[J].现代中西医结合杂志，2016，25（5）：499-500.
[19]	秦晓莉.沙美特罗替卡松粉雾化吸入治疗儿童支气管哮喘的临床研究[J].中国医药导刊，2016，18（7）：703-704.
[20]	马旭升，涂林修，梅依君，等.儿童哮喘规范化管理治疗效果评价[J].临床儿科杂志，2015，33（8）：706-709.